CPT® Code 91322

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use

The CPT® Code 91322 refers to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, specifically the mRNA-LNP formulation, which is designed for intramuscular use. This vaccine is crucial in providing protection against COVID-19, a disease caused by the SARS-CoV-2 virus, which can lead to severe and potentially life-threatening health complications. The vaccine utilizes messenger RNA (mRNA) technology, where strands of mRNA are encapsulated in lipid nanoparticles (LNP). This innovative approach allows the mRNA to instruct the body's cells to produce a protein that mimics the spike protein found on the surface of the coronavirus. By doing so, the immune system is prompted to recognize this protein as foreign, leading to the production of antibodies that can effectively combat the virus upon exposure. The specific formulation referenced by this code encodes for the spike protein of the SARS-CoV-2 Omicron variant lineage XBB.1.5. Administered intramuscularly, this vaccine does not require additional adjuvants to enhance the immune response, as the lipid nanoparticle system facilitates the uptake of mRNA by the cells. This code is specifically for reporting the supply of the Moderna COVID-19 vaccine at a dosage of 50 mcg/0.5 mL, intended for individuals aged 12 years and older. The formulation includes buffering agents that stabilize the vaccine and maintain its pH, allowing for storage at standard refrigerator temperatures. It is important to note that the administration of the vaccine is reported separately from the supply code.